Cost analysis comparing an anthracycline/docetaxel regimen to CMF in patients with early stage breast cancer.
In: Onkologie, Jg. 32 (2009-09-01), Heft 8-9, S. 473-81
academicJournal
Zugriff:
Background: Taxane-based adjuvant chemotherapy is the current standard for node-positive breast cancer patients. Recent data identified relevant patient subgroups with questionable benefit. To estimate the incremental burden on health care resources and costs, we compared a modern sequential regimen (4x epirubicin/cyclophosphamide; 4x docetaxel: EC-->DOC) to CMF.
Patients and Methods: Data were obtained alongside the phase III WSG-AGO Intergroup trial (2000-2005). A cohort of 110 patients receiving 1,047 chemotherapy cycle days at 38 study sites was analyzed from a hospital perspective.
Results: Mean age was 52.4 years. Mean costs for the EC-->DOC group (n = 54) totaled euro8,459 per patient (95% confidence interval (CI): euro7,785-9,132) with cytostatic drug costs being the largest burden (euro5,673; 67%). CMF was significantly (-41.2%) less expensive (euro4,973; 95% CI: euro4,706-5,240), and toxicity-associated rehospitalization was reduced by half (CMF: n = 4, EC-->DOC:n =8).
Conclusions: Our results demonstrate a substantial budget increase attributable to introduction of taxanes to adjuvant chemotherapy of breast cancer. Data will allow estimating cost-effectiveness of individualized chemotherapy strategies.
| Titel: |
Cost analysis comparing an anthracycline/docetaxel regimen to CMF in patients with early stage breast cancer.
|
|---|---|
| Autor/in / Beteiligte Person: | Braun, M ; Jacobs, VR ; Wagenpfeil, S ; Sattler, D ; Harbeck, N ; Nitz, U ; Bernard, R ; Kuhn, W ; Ihbe-Heffinger, A |
| Zeitschrift: | Onkologie, Jg. 32 (2009-09-01), Heft 8-9, S. 473-81 |
| Veröffentlichung: | Basel, New York, Karger., 2009 |
| Medientyp: | academicJournal |
| ISSN: | 1423-0240 (electronic) |
| DOI: | 10.1159/000226211 |
| Schlagwort: |
|
| Sonstiges: |
|